Reproductive Biology and Endocrinology (Jul 2022)

A loss-of-function variant in SSFA2 causes male infertility with globozoospermia and failed oocyte activation

  • Gelin Huang,
  • Xueguang Zhang,
  • Guanping Yao,
  • Lin Huang,
  • Sixian Wu,
  • Xiaoliang Li,
  • Juncen Guo,
  • Yuting Wen,
  • Yan Wang,
  • Lijun Shang,
  • Na Li,
  • Wenming Xu

DOI
https://doi.org/10.1186/s12958-022-00976-5
Journal volume & issue
Vol. 20, no. 1
pp. 1 – 13

Abstract

Read online

Abstract Globozoospermia (OMIM: 102530) is a rare type of teratozoospermia ( A; p.R1224Q) in the patient. This variant significantly reduced the protein expression of SSFA2. Immunofluorescence staining showed positive SSFA2 expression in the acrosome of human sperm. Liquid chromatography–mass spectrometry/mass spectrometry (LC–MS/MS) and Coimmunoprecipitation (Co-IP) analyses identified that GSTM3 and Actin interact with SSFA2. Further investigation revealed that for the patient, regular intracytoplasmic sperm injection (ICSI) treatment had a poor prognosis. However, Artificial oocyte activation (AOA) by a calcium ionophore (A23187) after ICSI successfully rescued the oocyte activation failure for the patient with the SSFA2 variant, and the couple achieved a live birth. This study revealed that SSFA2 plays an important role in acrosome formation, and the homozygous c.3671G > A loss-of-function variant in SSFA2 caused globozoospermia. SSFA2 may represent a new gene in the genetic diagnosis of globozoospermia, especially the successful outcome of AOA-ICSI treatment for couples, which has potential value for clinicians in their treatment regimen selections.

Keywords